Alimera Sciences

Alimera Sciences is a global leader in retinal therapies, delivered via an innovative intravitreal implant. Their flagship product, ILUVIEN, is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid.

/Company Profile

Industries icon
Location
United States
Industries icon
Salesforce Users
50+
Industries icon
Industry
Life Sciences
Industries icon
Solutions
CT Mobile

/Challenges

The Alimera Sales Operations team wanted to utilize Salesforce Maps to support territory planning, alignment, and management. Their legacy Salesforce automation provider did not integrate with Maps, so Salesforce connected Alimera with Customertimes and encouraged them to evaluate CT Mobile, a suite of Salesforce-based solutions that supports the unique requirements of Life Sciences sales teams.

/Solutions

The Alimera Sciences project became the first US-based implementation of CT Mobile. With just 12 weeks from contract to go-live, Alimera found the agile implementation methodology they were looking for:

  • Mobile and offline functionality with hybrid real-time options
  • Pharma & med device data models
  • A remote sales console for inside sales and field reps
  • HCP engagement with a 360° customer view that includes affiliates
  • KOL/medical CRM features with influence maps
  • Digital and remote detailing, including interactive data capture
  • PDMA-compliant sample management with signature capture and audit
  • Order management and rep training

/Results

Alimera replaced their legacy SFA with Customertimes and CT Mobile and realized significant benefits:

  • Ease of integration with Maps and other key Salesforce applications
  • Unlimited flexibility to create/define affiliations between accounts and contacts
  • A true 360° view of customer relationships
  • Administration via the Salesforce Lightning Console, enabling them to become self-sufficient when making configuration changes
  • Remote detailing, included with CT Mobile at no extra charge
  • A three-year cost savings of more than 20% in both license fees and ongoing support